ESTRO 2024 - Abstract Book

S408

Brachytherapy - Urology

ESTRO 2024

Conclusion:

The combination of 5-fraction ultrahypofractionated prostate SBRT with LDR brachytherapy is well tolerated by patients in the short term, and acute side effects are rare. This short-course treatment may be not only an effective, but also cost-effective method for prostate cancer. Further analyses and longer follow-up are are needed to establish the benefit of combining LDR brachytherapy with prostate SBRT.

Keywords: SBRT, 5*5, LDR

References:

Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer - Results From a Prospective Trial. Marisa A. Kollmeier, MD,* Sean McBride, MD,* et al. lnL J Radiation Oncol Biol Phys. Vol. 108, No. 4, pp. 905-913, 2020 https://doi.org/ 10. J O 16/j.ijrobp.2020.05.032

1131

Digital Poster

Similar toxicity in Brachytherapy vs EBRT in prostate cancer: PROMs from single institutional study.

Ignacio Visus 1 , Maria Isabel Martínez 1 , Margarita Illas 2 , Uxue Zarandona 3 , Marta Barrado 1 , Amaya Sola 1 , Irene Martínez 1 , Sonia Flamarique 1 , Mikel Rico 1 , Villanueva Raquel 4 , Garcia Noelia 4 , Fuentemilla Naiara 5 , Santiago Pellejero 5 , Erkuden Burillo 1 , M.Ujué Ruiz 1 , Libe Almondarain 1 , Darwin Pozo 1 , Villafranca Elena 1 , Martínez Enrique 1 1 Universitary Hospital of Navarre, Radiation Oncology, Pamplona, Spain. 2 Navarrabiomed Research Center, Radiation Oncology, Pamplona, Spain. 3 Universitary Hospital of Navarre, Psicooncology, Pamplona, Spain.